The two fACEs of the tissue renin-angiotensin systems: Implication in cardiovascular diseases

Current Pharmaceutical Design

Volumn 13, Issue 12, 2007, Pages 1231-1245

  Lazartigues, Eric ^a   Feng, Yumei ^a   Lavoie, Julie L ^b  

^a Medical Center   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

ACE polymorphism; Heart failure; Hypertension; Membrane bound ACE2 protein; Severe acute respiratory syndrome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; OLMESARTAN; RAMIPRIL; RETINOIC ACID; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME POLYMORPHISM; ENZYME STRUCTURE; HEART FAILURE; HEART INFARCTION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME;

ANIMALS; AUTOCRINE COMMUNICATION; BRAIN; CARDIOVASCULAR DISEASES; HUMANS; ORGAN SPECIFICITY; PARACRINE COMMUNICATION; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 34248388973     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618911     Document Type: Review

References (166)

1. Lavoie JL, Sigmund CD. Overview of the renin-angiotensin system-An endocrine and paracrine system. Endocrinology 2003; 144: 2179-83.
2. Davisson RL. Physiological genomic analysis of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2003; 285: 498-511.
3. Sun Y, Weber KT. RAS and connective tissue in the heart. Int J Biochem Cell Biol 2003; 35: 919-31.
4. Xiao HD, Fuchs S, Frenzel K, Teng L, Li P, Shen XZ, et al. The use of knockout mouse technology to achieve tissue selective expression of angiotensin converting enzyme. J Mol Cell Cardiol 2004; 36: 781-9.
5. Kondoh G, Tojo H, Nakatani Y, Komazawa N, Murata C, Yamagata K, et al. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat Med 2005; 11: 106-6.
6. Oppong SY, Hooper NM. Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane. Biochem J 1993; 292: 597-603.
7. Esther CR Jr, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, et al. The Critical Role of Tissue Angiotensin-converting Enzyme as Revealed by Gene Targeting in Mice. J Clin Invest 1997; 99: 2375-85.
8. Esther CR Jr, Howard TE, Marino EM, Goddard MJ, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996; 74: 953-65.
9. Krege JH, John SWM, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995; 375: 146-8.
10. Waeber B, Nussberger J, Juillerat L, Brunner HR. Angiotensin converting enzyme inhibition: Discrepancy between antihypertensive effect and suppression of enzyme activity. J Cardiovasc Pharmacol 1989; 14: 53-9.
11. Hamdi HK, Castellon R. A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. Biochem Biophys Res Commun 2004; 318: 187-91.
12. Mata-Balaguer T, de la Herran R, Ruiz-Rejon C, Ruiz-Rejon M, Garrido-Ramos MA, Ruiz-Rejon F. Angiotensin-converting enzyme and p22phox polymorphisms and the risk of coronary heart disease in a low-risk Spanish population. Int J Cardiol 2004; 95: 145-51.
13. Rigat B, Hubert F, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
14. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
15. Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet 2004; 115: 91-6.
16. Danser AH, Deinum J, Osterop A, Admiraal P, Schalekamp M. Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. J Hypertens 1999; 17: 1867-72.
17. Ueda S, Elliott HL, Morton JJ, Connell JMC. Enhanced Pressor Response to Angiotensin I in Normotensive Men With the Deletion Genotype (DD) for Angiotensin-Converting Enzyme. Hypertension 1995; 25: 1266-9.
18. van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, Chang PC. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol 2000; 35: 484-90.
19. Danser AH, Derkx FH, Hense HW, Jeunemaitre X, Riegger GA, Schunkert H. Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 1998; 16: 1879-83.
20. Kim HS, Lee G, John SWM, Maeda N, Smithies O. Molecular phenotyping for analyzing subtle genetic effects in mice: Application to an angiotensinogen gene titration. Proc Natl Acad Sci USA 2002; 99: 4602-7.
21. Chadwick IG, O'Toole L, Morice AH, Yeo WW, Jackson PR, Ramsay LE. Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes. J Cardiovasc Pharmacol 1997; 29: 485-9.
22. Morimoto S, Cassell MD, Beltz TG, Johnson AK, Davisson RL, Sigmund CD. Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ Res 2001; 89: 365-72.
23. Morimoto S, Cassell MD, Sigmund CD. Glial- and neuronal-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference. J Biol Chem 2002; 277: 33235-41.
24. Lavoie JL, Lake-Bruse KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol 2004; 286: F965-71.
25. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995; 44: 267-72.
26. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970; 214: 374-6.
27. Hecker M, Blaukat A, Bara AT, Muller-Esterl W, Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol 1997; 121: 1475-81.
28. Hecker M, Bara AT, Busse R. Potentiation of the biological efficacy of bradykinin by ACE inhibitors: A shift in the affinity of the B2 receptor? Immunopharmacology 1996; 33: 93-4.
29. Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, et al. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors: The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res 1997; 81: 848-56.
30. Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Busse R. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99: 2034-40.
31. Kurdi M, De Mello WC, Booz GW. Working outside the system: An update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol 2005; 37: 1357-67.
32. Fleming I, Kohlstedt K, Busse R. New fACEs to the renin-angiotensin system. Physiology 2005; 20: 91-5.
33. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
34. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43.
35. Komatsu T, Suzuki Y, Imai J, Sugano S, Hida M, Tanigami A, et al. Molecular cloning, mRNA expression and chromosomal localization of mouse angiotensin-converting enzyme-related carboxypeptidase (mACE2). DNA Seq 2002; 13: 217-20.
36. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8.
37. Huentelman MJ, Zubcevic J, Katovich MJ, Raizada MK. Cloning and characterization of a secreted form of angiotensin-converting enzyme 2. Regul Pept 2004; 122: 61-7.
38. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005; 280: 30113-9.
39. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-43.
40. Lin Q, Keller RS, Weaver B, Zisman LS. Interaction of ACE2 and integrin beta1 in failing human heart. Biochim Biophys Acta 2004; 1689: 175-8.
41. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004; 279: 17996-8007.
42. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23: 177-83.
43. Benjafield AV, Wang WYS, Morris BJ. No Association of Angiotensin-Converting Enzyme 2 Gene (ACE2) Polymorphisms With Essential Hypertension. Am J Hypertens 2004; 17: 624-8.
44. Huang W, Yang W, Wang Y, Zhao Q, Gu D, Chen R. Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese. J Hum Hypertens 2006; 20: 968-71.
45. Lieb W, Graf J, Gotz A, Konig IR, Mayer B, Fischer M, et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men Results of the MONICA Augsburg echocardiographic substudy. J Mol Med 2006; 84: 88-96.
46. Zhong J, Yan Z, Liu D, Ni Y, Zhao Z, Zhu S, et al. Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. J Lab Clin Med 2006; 147: 91-5.
47. Zhang H, Wada J, Hida K, Tsuchiyama Y, Hiragushi K, Shikata K, et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 2001; 276: 17132-9.
48. Douglas GC, O'Bryan MK, Hedger MP, Lee DK, Yarski MA, Smith AI, et al. The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis. Endocrinology 2004; 145: 4703-11.
49. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107-10.
50. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116: 2218-25.
51. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004; 29: 419-27.
52. Strawn WB, Richmond RS, Tallant EA, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 2004; 126: 120-6.
53. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-75.
54. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RA. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept 2005; 125: 29-34.
55. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol 2004; 204: 587-93.
56. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-7.
57. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, et al. ACE and ACE2 Activity in Diabetic Mice. Diabetes 2006; 55: 2132-9.
58. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: A renoprotective combination? Hypertension 2004; 43: 1120-5.
59. Hong OK, Suh SH, Kwon HS, Ko SH, Choi YH, Moon SD, et al. Proteomic analysis of differential protein expression in response to epidermal growth factor in neonatal porcine pancreatic cell monolayers. J Cell Biochem 2005; 95: 769-81.
60. Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 2005; 288: F353-62.
61. Brosnihan KB, Neves LAA, Joyner J, Averill DB, Chappell MC, Sarao R, et al. Enhanced Renal Immunocytochemical Expression of ANG-(1-7) and ACE2 During Pregnancy. Hypertension 2003; 42: 749-53.
62. Brosnihan KB, Neves LA, Anton L, Joyner J, Valdes G, Merrill DC. Enhanced expression of Ang-(1-7) during pregnancy. Braz J Med Biol Res 2004; 37: 1255-62.
63. Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, et al. Developmental expression of ACE2 in the SHR kidney: A role in hypertension? Kidney Int 2006; 70: 34-41.
64. Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, et al. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004; 44: 907-12.
65. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-9.
66. Oparil S, Tregear GW, Koerner T, Barnes BA, Haber E. Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog. Circ Res 1971; 29: 682-90.
67. Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ. Angiotensin-Converting Enzyme-2 (ACE2): Comparative Modeling of the Active Site, Specificity Requirements, and Chloride Dependence. Biochem J 2003; 42: 13185-92.
68. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; 383: 45-51.
69. Shaltout HA, Westwood B, Averill DB, Ferrario CM, Figueroa J, Diz DI, et al. Angiotensin metabolism in renal proximal tubules, urine and serum of sheep: Evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol 2006 Aug 8; [Epub ahead of print].
70. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006; 48: 572-8.
71. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased Angiotensin-(1-7)-Forming Activity in Failing Human Heart Ventricles: Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2. Circulation 2003; 108: 1707-12.
72. Benter IF, Diz DI, Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 1995; 26: 1138-44.
73. Eatman D, Wang M, Socci RR, Thierry-Palmer M, Emmett N, Bayorh MA. Gender differences in the attenuation of salt-induced hypertension by angiotensin (1-7). Peptides 2001; 22: 927-33.
74. Ferrario CM. Angiotension-(1-7) and antihypertensive mechanisms. J Nephrol 1998; 11: 278-83.
75. Yan ZH, Ren KJ, Wang Y, Chen S, Brock TA, Rege AA. Development of intramolecularly quenched fluorescent peptides as substrates of angiotensin-converting enzyme 2. Anal Biochem 2003; 312: 141-7.
76. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002; 124: 11852-3.
77. Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanyal I, et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 2003; 278: 15532-40.
78. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198-211.
79. Pugsley MK. The opioid receptor independent actions of kappa receptor agonists in the cardiovascular system. Curr Pharm Des 2004; 10: 2429-44.
80. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG. Activation of bradykinin B1 receptor by ACE inhibitors. Int Immunopharmacol 2002; 2: 1787-93.
81. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450-4.
82. Nie Y, Wang P, Shi X, Wang G, Chen J, Zheng A, et al. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun 2004; 321: 994-1000.
83. Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992; 357: 420-2.
84. Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 2004; 314: 235-41.
85. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS, coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2006 May 15; [Epub ahead of print].
86. Li W, Greenough TC, Moore MJ, Vasilieva N, Somasundaran M, Sullivan JL, et al. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J Virol 2004; 78: 11429-33.
87. Schuijt MP, Danser AHJ. Cardiac angiotensin ii: An intracrine hormone? Am J Hypertens 2002; 15: 1109-16.
88. Danilov SM, Faerman AI, Printseva O, Martynov AV, Sakharov I, Trakht IN. Immunohistochemical study of angiotensin-converting enzyme in human tissues using monoclonal antibodies. Histochemistry 1987; 87: 487-90.
89. Hokimoto S, Yasue H, Fujimoto K, Yamamoto H, Nakao K, Kaikita K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996; 94: 1513-8.
90. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol Cell Physiol 1992; 263: C851-63.
91. Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc. Res 1994; 28: 1423-32.
92. Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S, et al. Cellular Distribution of Angiotensin-Converting Enzyme After Myocardial Infarction. Hypertension 1995; 25: 219-26.
93. Nagano M, Higaki J, Mikami H, Nakamura M, Higashimori K, Katahira K, et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9: 595-9.
94. Nagano M, Higaki J, Nakamura F, Higashimori K, Nagano N, Mikami H, et al. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 1992; 19: 708-12.
95. Bohm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163: 217-21.
96. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular Damage without Hypertension in Transgenic Rats Expressing Prorenin Exclusively in the Liver. J Clin Invest 1996; 98: 1966-70.
97. Prescott G, Silversides DW, Chiu SM, Reudelhuber TL. Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. Physiol Genomics 2000; 4: 67-73.
98. Mazzolai L, Nussberger J, Aubert JF, Brunner DB, Gabbiani G, Brunner HR, et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998; 31: 1324-30.
99. Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci USA 1997; 94: 6391-6.
100. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000; 97: 931-6.
101. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased Cardiac Angiotensin II Levels Induce Right and Left Ventricular Hypertrophy in Normotensive Mice. Hypertension 2000; 35: 985-1.
102. Higaki J, Aoki M, Morishita R, Kida I, Taniyama Y, Tomita N, et al. In Vivo Evidence of the Importance of Cardiac Angiotensin-Converting Enzyme in the Pathogenesis of Cardiac Hypertrophy. Arterioscler Thromb Vasc Biol 2000; 20: 428-4.
103. Bader M. Role of the Local Renin-angiotensin System in Cardiac Damage: A Minireview Focussing on Transgenic Animal Models. J Mol Cell Cardiol 2002; 34: 1455-62.
104. Hoffmann S, Krause T, Geel P, Willenbrock R, Pagel I, into YM, et al. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. J Mol Med 2001; 79: 601-8.
105. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippoldt A, Hoffmann S, et al. Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet 2004; 13: 1441-50.
106. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC, Jr, Kasi VS, et al. Mice with cardiac-restricted Angiotensin-Converting Enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165: 1019-32.
107. Donoghue M, Wakimoto S, Maguire CT, Acton S, Hales P, Stagliano N, et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003; 35: 1043-53.
108. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: Shared and distinct genes in the development of heart failure. Physiol Genomics 2005; 21: 299-07.
109. London B. A second ACE of hearts. J Mol Cell Cardiol 2003; 35: 1009-10.
110. Gustein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, et al. Conduction Slowing and Sudden Arrhythmic Death in Mice With Cardiac-Restricted Inactivation of Connexin43. Circ Res 2001; 88: 333-9.
111. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005; 90: 783-90.
112. Katovich MJ, Grobe JL, Huentelman MJ, Raizada MK. Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Exp Physiol 2005; 90: 299-305.
113. Diez-Freire C, Vazquez J, Correa de Adjounian MF, Ferrari MFR, Yuan L, Silver X, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 2006; 27: 12-9.
114. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation 1998; 97: 282-9.
115. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. New Engl J Med 1999; 341: 577-85.
116. Zucker IH, Wang W, Pliquett RU, Liu JL, Fatel KP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann N Y Acad Sci 2001; 940: 431-43.
117. Studer P, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994; 94: 301-10.
118. Battle M, Roig E, Perez-Villa F, Lario S, Cejudo-Martin P, Garcia-Pras E, et al. Increased Expression of the Renin-Angiotensin System and Mast Cell Density But Not of Angiotensin-converting Enzyme II in Late Stages of Human Heart Failure. J Heart Lung Transplant 2006; 25: 1117-25.
119. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86: 1913-20.
120. Zhang X, Dostal DE, Reiss K, Cheng W, Kajstura J, Li P, et al. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes. Am J Physiol Heart Circ Physiol 1995; 269: H1791-802.
121. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991; 69: 475-82.
122. Shao Q, Ren B, Elimban V, Tappiab PS, Takeda N, Dhalla NS. Modification of sarcolemmal Na+-K+-ATPase and Na+/Ca2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol 2005; 288: H2637-46.
123. Barlucchi L, Leri A, Dostal DE, Fiordaliso F, Tada H, Hintze TH, et al. Canine Ventricular Myocytes Possess a Renin-Angiotensin System That Is Upregulated With Heart Failure. Circ Res 2001; 88: 298-304.
124. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-5.
125. Holtz J, Studer R, Reinecke H, Just H, Drexler H. Modulation of myocardial sarcoplasmic reticulum Ca(++)-ATPase in cardiac hypertrophy by angiotensin converting enzyme? Basic Res Cardiol 1992; 87: 191-204.
126. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95.
127. Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 2004; 22: 1971-6.
128. Ishiyama, Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-6.
129. Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 2005; 289: 1351-8.
130. Zisman LS. ACE and ACE2: A tale of two enzymes. Eur Heart J 2005; 26: 322-4.
131. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-10.
132. Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004; 61: 2720-7.
133. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2004; 2: 19.
134. Ganten D, Lindpaintner K, Ganten U, Peters J, Zimmermann F, Bader M, et al. Transgenic rats: New animal models in hypertension research. Invited lecture. Hypertension 1991; 17: 843-55.
135. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: New insights from experimental animal models in hypertension research. J Mol Med 2001; 79: 76-102.
136. Keidar S, Strizevsky A, Raz A, Gamliel-Lazarovich A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrol Dial Transplant 2006 Nov 9; [Epub ahead of print].
137. Johnson AK, Thunhorst RL. The neuroendocrinology of thirst and salt appetite: Visceral sensory signals and mechanisms of central integration. Frontiers Neuroendocrinol 1997; 18: 292-353.
138. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, et al. The brain renin-angiotensin system: Location and physiological roles. Int J Biochem Cell Biol 2003; 35: 901-18.
139. Unger T, Badoer E, Ganten D, Lang RE, Rettig R. Brain angiotensin: pathways and pharmacology. Circulation 1988; 77: 140-54.
140. Lippoldt A, Paul M, Fuxe K, Ganten D. The brain renin-angiotensin system: Molecular mechanisms of cell to cell interactions. Clin Exp Hypertens 1995; 17: 251-66.
141. Lazartigues E, Dunlay SM, Loihl AK, Sinnayah P, Lang JA, Espelund JJ, et al. Brain-selective overexpression of angiotensin (AT1) receptors causes enhanced cardiovascular sensitivity in transgenic mice. Circ Res 2002; 90: 617-24.
142. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, Johnson AK. Heart failure and the brain: New perspectives. Am J Physiol Regul Integr Comp Physiol 2003; 284: R259-76.
143. Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss HP, et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 2005; 26: 1270-7.
144. Elased KM, Cunha TS, Gurley SB, Coffman TM, Morris M. New Mass Spectrometric Assay for Angiotensin-Converting Enzyme 2 Activity. Hypertension 2006; 47: 1010-7.
145. Kuhn JH, Li W, Choe H, Farzan M. Whats new in the renin-angiotensin system? Angiotensin-converting enzyme 2: A functional receptor for SARS coronavirus. Cell Mol Life Sci 2004; 61: 2738-43.
146. Hung ECW, Chim SSC, Chan PKS, Tong YK, Ng EKO, Chiu RWK, et al. Detection of SARS Coronavirus RNA in the Cerebrospinal Fluid of a Patient with Severe Acute Respiratory Syndrome. Clin Chem 2003; 49: 2108-9.
147. He L, Ding YQ, Che XY, Zhang QL, Huang ZX, Wang HJ, et al. Expression of the monoclonal antibody against nucleocapsid antigen of SARS-associated coronavirus in autopsy tissues from SARS patients. Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 1128-30.
148. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-7.
149. Glass WG, Subbaro K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 2004; 173: 4030-9.
150. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004; 319: 1216-21.
151. Wang P, Chen J, Zheng A, Nie Y, Shi X, Wang W, et al. Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Commun 2004; 315: 439-44.
152. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006; 290: C420-6.
153. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2006 Aug 31; [Epub ahead of print].
154. Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, Santos RA. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol 1992; 263: R89-94.
155. Santos RAS, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): An update. Regul Pept 2000; 91: 45-62.
156. Averill DB, Diz DI. Angiotensin peptides and baroreflex control of sympathetic outflow:pAthways and mechanisms of the medulla oblongata. Brain Res Bull 2000; 51: 119-28.
157. Oliveira DR, Santos RAS, Santos GFP, Khosla MC, Campagnole-Santos MJ. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 1996; 27: 1284-90.
158. Gironacci MM, Valera MS, Yujnovsky I, Pena C. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 2004; 44: 783-7.
159. Lima CV, Paula RD, Resende FL, Khosla MC, Santos RAS. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 1997; 30: 542-8.
160. Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA 1988; 85: 4095-8.
161. Santos RAS, Silva ACS, Maric C, Silva DMR, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
162. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, et al. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int 2002; 62: 1349-57.
163. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005; 38: 499-507.
164. Blacher J, Protogerou AD, Safar ME. Large artery stiffness and antihypertensive agents. Curr Pharm Des 2005; 11(25): 3317-26.
165. Buemi M, Aloisi C, Fulvio F, Caccamo C, Cavallaro E, Crasci E, et al. Cardiorenal consequences of atherosclerosis and statins therapy: From the past to the future. Curr Pharm Des 2005; 11 (30): 3973-84.
166. Wang JG. Perspectives of new antihypertensive drugs. Curr Pharm Des 2005; 11 (25): 3273.